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Background: MUC4 plays important roles in the malignant progression of human pancreatic cancer. But the huge
length of MUC4 gene fragment restricts its functional and mechanism research. As one of its splice variants, MUC4/
Y with coding sequence is most similar to that of the full-length MUC4 (FL-MUC4), together with alternative splicing
of the MUC4 transcript has been observed in pancreatic carcinomas but not in normal pancreas. So we speculated
that MUC4/Y might be involved in malignant progression similarly to FL-MUC4, and as a research model of MUC4
in pancreatic cancer. The conjecture was confirmed in the present study.
Methods: MUC4/Y expression was detected by real-time quantitative reverse transcription polymerase chain
reaction (qRT-PCR) using gene-specific probe in the clinic samples. The effects of MUC4/Y were observed by serial
in vitro and in vivo experiments based on stable over-expressed cell model. The underlying mechanisms were
investigated by sequence-based transcriptome analysis and verified by qRT-PCR, Western blot and enzyme-linked
immunosorbent assays.
Results: The detection of clinical samples indicates that MUC4/Y is significantly positive-correlated with tumor
invasion and distant metastases. Based on stable forced-expressed pancreatic cancer PANC-1 cell model, functional
studies show that MUC4/Y enhances malignant activity in vitro and in vivo, including proliferation under
low-nutritional-pressure, resistance to apoptosis, motility, invasiveness, angiogenesis, and distant metastasis.
Mechanism studies indicate the novel finding that MUC4/Y triggers malignancy-related positive feedback
loops for concomitantly up-regulating the expression of survival factors to resist adverse microenvironment
and increasing the expression of an array of cytokines and adhesion molecules to affect the tumor milieu.
(Continued on next page)* Correspondence: miaoyi@njmu.edu.cn; xuzekuan@njmu.edu.cn
†Equal contributors
1Department of General Surgery, First Affiliated Hospital, Nanjing Medical
University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, People’s
Republic of China
2Jiangsu Province Academy of Clinical Medicine, Institute of Tumor Biology,
Nanjing 210029, People’s Republic of China
Full list of author information is available at the end of the article
© 2014 Zhu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zhu et al. Journal of Translational Medicine 2014, 12:309 Page 2 of 23
http://www.translational-medicine.com/content/12/1/309(Continued from previous page)
Conclusions: In light of the enormity of the potential regulatory circuitry in cancer afforded by MUC4 and/or MUC4/
Y, repressing MUC4 transcription, inhibiting post-transcriptional regulation, including alternative splicing, or blocking
various pathways simultaneously may be helpful for controlling malignant progression. MUC4/Y- expression model is
proven to a valuable tool for the further dissection of MUC4-mediated functions and mechanisms.
Keywords: MUC4/Y, Alternative splicing, Pancreatic neoplasms, Cell movement, Angiogenesis, Neoplasm metastasis,
Gene expression regulation, Signal transductionBackground
Mucins are a family of high–molecular weight glycopro-
teins implicated in diverse biological function [1]. A mem-
ber of the transmembrane mucin family [2,3], mucin 4
(MUC4) has been mapped to chromosome 3 in the q29
region, which was cloned from the human tracheobron-
chial chromosomal DNA library and a human pancreatic
tumor cell line [2-5]. MUC4 plays important roles in the
carcinogenesis and progression of multiple human can-
cers, including pancreatic cancer [6,7]. MUC4 is aber-
rantly expressed in pancreatic ductal adenocarcinoma
(PDAC) and precancerous pancreatic intraepithelial neo-
plasias, but not in benign or normal parts of the pancreas
[8-10], and the level of expression correlates significantly
with poor prognosis of PDAC [10,11]. But because of the
huge length of its gene fragment (more than 30 KB), it is
incapable to clone and eukaryotic express the full-length
MUC4 gene. The function predictions and structure ana-
lyses of human MUC4 were mostly from the overexpres-
sion of its rat homologous gene rMuc4/SMC on human
tumor cells.
We have noticed that alternative splicing of the MUC4
transcript has been observed in pancreatic carcinomas
but not in normal pancreas [12-14]. MUC4 has a series of
splice variants (SV), including an SV1-21 isoform termed
SV0 (the full-length MUC4 [FL-MUC4]), MUC4/X, and
MUC4/Y. MUC4/Y has the coding sequence most similar
to that of FL-MUC4 [15]. Though it lacks the coding exon
2, MUC4/Y has the same exon sequences as FL-MUC4,
and the encoded protein has the same conserved domains
and a transmembrane β-subunit that contains three
epidermal growth factor (EGF) domains, a transmem-
brane sequence, a short cytoplasmic tail, and multiple
N-glycosylation sites as those in FL-MUC4. So we
speculated that MUC4/Y may be involved in carcino-
genesis and progression similarly to FL-MUC4. More
importantly, it may be as a research function model of
MUC4 in pancreatic cancer. Furthermore, based on
MUC4/Y, it is easy to construct the unique domain-
lacking models of MUC4 for its structure analyses and
mechanisms dissection.
Thus, the present study aimed to illustrate the role of
MUC4/Y in the progression of pancreatic cancer and
give insights into its downstream signaling effects: 1)Quantitatively assess MUC4/Y expression in tissue sam-
ples from PDAC patients using probe-specific primers
were done to illustrate the correlation of MUC4/Y
expression with clinicopathological factors and PDAC
patient survival. 2)Various in vitro and in vivo assays
were conducted using stable MUC4/Y-overexpressing
pancreatic cancer cell models to illustrate its function
in promoting the malignant properties of pancreatic
cancer. 3) The underlying molecular mechanisms were
investigated by sequence-based digital gene expression
(DGE) analysis and bioinformatics analyses to provide
full explanations.
Methods
Selection of patients and tissue specimens
We enrolled 108 patients for this retrospective study.
The patients had undergone pancreaticoduodenectomy
(Whipple resection) with histologically proven PDAC at
the Department of General Surgery of the First Affiliated
Hospital of Nanjing Medical University between 2006
and 2012. The Ethics Committee of the First Affiliated
Hospital of Nanjing Medical University (Permit Number:
2009-SR-031) approved this study. Each patient provided
informed consent.
The patients (61 men and 47 women; age range: 25–82
years; mean age: 60.98 ± 11.39 years) were regularly
followed until May 31, 2013. Overall survival (OS) was de-
fined as the time between surgery and death or the last
follow-up date. No patient died within one month after
surgery. Additional file 1: Table S1 summarizes the corre-
sponding characteristics of the patients; staging and grad-
ing were based on the sixth edition of the American Joint
Committee on Cancer guidelines [16].
Tissue samples were removed as soon as possible
after resection and divided into at least two bulk tissue
samples. A part of each sample was snap-frozen in
liquid nitrogen and then stored in liquid nitrogen until
used for RNA extraction. The remainder was fixed in
formalin, embedded in paraffin, and cut into 4-μm thick
sections for hematoxylin–eosin (H&E) staining. All tissue
samples were examined histologically; experienced pathol-
ogists confirmed the diagnosis. Histological grades of
tumor differentiation were assigned according to World
Health Organization criteria.
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and MUC4 by real-time reverse transcription–PCR with
specific primers
Following liquid nitrogen grinding, total RNA was ex-
tracted from bulk tissues with TRIzol (Life Technologies)
according to the manufacturer’s protocol. After spectro-
photometry quantification, 1 μg total RNA was used in a
final volume of 20 μL for reverse transcription (RT) with
an iScript cDNA Synthesis Kit ((Bio-Rad, CA, USA) ac-
cording to the manufacturer’s instructions. Quantitative
real-time PCR was performed using TaqMan Gene Ex-
pression Assays (Life Technologies) in a StepOnePlus
Real-Time PCR System (Life Technologies). Reactions
were performed in 10-μL volumes containing 1 μL di-
luted complementary DNA (cDNA), 20× TaqMan GeneFigure 1 Significant positive correlation between MUC4/Y mRNA exp
survival in PDAC. (A) Schematic representation of the design strategy for
on the difference between the exon sequences of MUC4/Y (NCBI Referenc
NM_018406.6). The TaqMan probe sequence lies in the exon 1–exon 3 jun
other MUC4 types encoding the exon 1–exon 2 junction, or MUC4/X (NCB
4 junction because it lacks the coding exons 2 and 3. Primers and TaqMan
different TNM stages. Scatter dot plots were drawn from the minimum ext
median. *P <0.05, **P ≤0.01, ***P ≤0.001. (C) Positive correlation between M
fitting. Regression equations were Y = 6.553 + 0.3212 × X + 0.02719 × X/2–0.0
and Y = 5.915 + 0.6127 × X (straight line). According to the correlation coeffici
threshold cycle value. (D) Kaplan–Meier survival curves of PDAC patients acco
using the log-rank test.Expression Assay Mix, and 2× TaqMan Universal PCR
Master Mix. The thermal cycling conditions comprised
initial denaturation at 95°C for 10 min and 40 cycles at
95°C for 15 s and 60°C for 1 min. The product number
of the MUC4 TaqMan Gene Expression Assay Mix was
Hs003666414 (Applied Biosystems). Figure 1A depicts
the specific primers (forward: 5′-TGGGTGTCCCTGA
GCTGC-3′, reverse: 5′-TGATGTGGCTGTGCGTCTC-
3′) and TaqMan probe (5′-ATGTGGTCCCAGGAATG
ACAACACCGT-3′) designed for MUC4/Y. In addition
to BLASTN searches, we performed RT-PCR with human
pancreatic cancer HPAC cell-lines using the MUC4/Y
forward and reverse primers, and the target PCR product
was subcloned into a pMD18-T vector for DNA sequen-
cing to ensure the specificity of each primer and confirmression level and TNM stage, MUC4 mRNA expression level, and
specific primers and TaqMan probe in MUC4/Y gene detection based
e Sequence: NM_004532.5) and FL-MUC4 (NCBI Reference Sequence:
ction; as exon 2 is absent, it detects MUC4/Y expression rather than
I Reference Sequence: NM_138297.4), which encodes the exon 1–exon
probe are underlined. (B) Comparison of MUC4/Y mRNA expression at
ending to the maximum; the center horizontal line denotes the sample
UC4/Y and MUC4 mRNA expression (R2 = 0.430, P <0.001) and curve
0033333 × X/3 (cubic), Y = 6.522 + 0.3514 × X + 0.02102 × X/2 (quadratic),
ent value, the cubic or quadratic curve model was the better model. Ct,
rding to MUC4/Y mRNA expression status. The P-value was calculated
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(Hs099999901_s1; Applied Biosystems) was used as the
internal control for each sample to calibrate the original
concentration of mRNA [17]. Relative gene expression
was calculated by subtracting the threshold cycle (Ct)
value of the target genes and 18S rRNA (control) genes
using the 2-ΔCt method [18]. Each quantification PCR was
performed in triplicate and repeated thrice independently.Cell culture and stable overexpression of MUC4/Y
The PANC-1 pancreatic cancer cell line was obtained
from the Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences, and grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing high glu-
cose (Wisent Biocenter, Canada) and supplemented
with 10% (v/v) fetal bovine serum (FBS; Wisent Biocen-
ter, Canada) and penicillin–streptomycin (HyClone,
Thermo, USA) at 37°C in a humidified atmosphere
containing 5% CO2.
We designed full-length cDNA fragments encoding
the MUC4/Ygene, i.e., human MUC4 cell surface–associated
transcript variant 4 (NCBI Reference Sequence: NM_004
532.5, GI:336285420) containing a Kozak sequence
(GCCACC) before the ATG initiation codon for opti-
mal translation and with unique restriction sites present
in the multiple clone site (MCS) of the lentiviral vector
but absent from the MUC4/Y cDNA sequence. The target
sequence was synthesized and cloned in a pUC57 vector
(GenScript). Then, the cDNA encoding MUC4/Y was sub-
cloned into the lentiviral vector pCDH-CMV-MCS-EF1-
Puro (Cat. #CD510B-1, System Biosciences, USA). To gen-
erate viral particles, 293 T cells were transiently transfected
with pCDH-CMV-MCS-EF1-Puro/MUC4/Y and the
pPACKH1 Lentivector Packaging Kit (Cat. #LV500A-1,
System Biosciences, USA) with Lipofectamine 2000
(Invitrogen Life Technology) according to the manufac-
turer’s instructions. The virus titer was detected with
quantitative real-time PCR after concentrating and har-
vesting the viral supernatant 48 h after transfection. At
24 h after plating, stable transduction of PANC-1 cells
was carried out at 20 multiplicity of infection with the
virus and using polybrene (8 μg/mL; Sigma-Aldrich) to
augment infection efficiency. Stable clones were then
selected in medium containing puromycin (2 μg/mL;
Sigma-Aldrich).
Using real-time PCR, western blotting, and immunofluor-
escence, we detected the mRNA and protein expression
and location of the target genes. Stable transfected PANC-1
cells overexpressing the MUC4/Y gene were designated
PANC-1-MUC4/Y; PANC-1 cells transfected with empty
lentiviral vectors (EV) were designated PANC-1-EV. Wild-
type PANC-1 and PANC-1-EV cells were used as blank
and negative control groups, respectively. No differenceswere observed between the PANC-1-EV and wild-type
PANC-1 cells.Western blotting
PANC-1–derived clones were processed for protein ex-
traction and western blotting using standard procedures.
Cell lysates were prepared as described previously [19].
After the concentrations were determined using the Brad-
ford assay, proteins (30 μg/lane) were resolved on 4-20%
Mini-PROTEAN TGX precast gels (#456-1093; Bio-Rad).
The resolved proteins were transferred onto polyvinyli-
dene difluoride membranes, blocked with 5% non-fat milk
in phosphate-buffered saline (PBS) for 2 h, and subjected
to standard immunodetection procedures using specific
antibodies. The following primary antibodies were used to
label the membranes: 1 μg/mL anti-MUC4 mouse mono-
clonal antibody (ab60720; Abcam, Cambridge, UK) and
anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mouse monoclonal antibody (1:1000, AG019; Beyotime,
CHINA). The membranes were incubated at 4°C over-
night, followed by six 10-min washes in TBST [50 mmol/
L Tris–HCl (pH 7.4), 150 mmol/L NaCl, 0.05% Tween 20],
and were incubated with horseradish peroxidase–labeled
goat anti-mouse immunoglobulin G (IgG, 1:2000; #A0216;
Beyotime) for 1 h at room temperature, followed by six 10-
min washes with TBST. The blots were developed with an
enhanced chemiluminescence kit (Amersham, Freiburg,
Germany). The internal molecular weight standard was
PageRuler Plus Prestained Protein Ladder (#26619/
SM1811, 10–250 kD; Fermentas).Immunofluorescence
Cells cultured to 70% confluence were washed with
0.1 mol/L HEPES containing Hanks’ buffer and fixed
with Immunol Staining Fix Solution (#P0098; Beyotime)
at room temperature for 15 min. After three 10-min
washes in Immunol Staining Wash Buffer (#P0106; Beyo-
time), the fixed cells were blocked in Immunol Staining
Blocking Buffer (#P0102; Beyotime) for 60 min at room
temperature for nonspecific blocking, followed by incuba-
tion at 4°C overnight with anti-MUC4 mouse monoclonal
antibody (1:100 in PBS, ab60720; Abcam). Cells were
washed 3–5 times for 10 min with PBS containing 0.05%
Tween 20 (PBS-T) and then incubated with cyanine 3–
labeled goat anti-mouse secondary antibodies (#P0193;
Beyotime) at 37°C for 60 min. The cells were washed again
3–5 times for 10 min with PBS-T. Nuclei were counter-
stained with diaminophenylindole (0.5 μg/mL) for 5 -
minutes. Immunostaining was observed under a Nikon
Ti-E inverted fluorescence microscope; representative
photographs were captured using NIS-Elements D4.0 soft-
ware (Nikon).
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Cell proliferation was determined using Cell Counting
Kit-8 (#C0038; Beyotime) according to the manufacturer’s
instructions. Briefly, 1 × 103 cells/well were seeded in a 96-
well flat-bottomed plate and grown at 37°C for 24, 48, 72,
96, and 120 h. Cells were grown in high- (10% FBS) or
low-serum (1% FBS) medium. After 10 μL WST-8 dye was
added to each well, cells were incubated at 37°C for 4 h
and the absorbance at 450 nm determined using a micro-
plate reader.
Apoptosis assay
Many agents, including the clinically useful sorafenib,
can induce apoptosis [20]. Following 24-h treatment
with 8 μM sorafenib, PANC-1–derived clones were tryp-
sinized, washed with cold PBS, and resuspended in PBS.
The advantage of 7-amino-actinomycin D (7-AAD) over
propidium iodide is that there is minimal spectral over-
lap between the emissions. We used a fluorescein iso-
thiocyanate (FITC) Annexin V Apoptosis Detection Kit
with 7-AAD (#640922; BioLegend, USA) according to
the manufacturer’s instructions. Briefly, 5 μL FITC–
annexin V and 5 μL 7-AAD Viability Staining Solution
(#00-6993; eBioscience, USA) were added to a 100-μL
cell suspension (1 × 106 cells) in binding buffer. The cells
were gently vortexed and incubated for 15 min at room
temperature in the dark, and 400 μL binding buffer was
added for flow cytometric analysis using a FACScan
Flow Cytometer (Becton Dickinson).
Cell migration and invasion assays
We used modified 24-well Boyden chambers for the cell
migration and invasion assays. The top chamber (Trans-
well) containing a polycarbonate filter membrane (8-μm
pore size; BD Labware) was inserted into a 24-well plate
(bottom chamber); a Transwell filter membrane coated
with 40 μL Matrigel (BD Biosciences) was used in the in-
vasion assay. Medium containing 10% FBS was placed in
the bottom chamber as a chemoattractant. Cells (3 × 105)
in 300 μL serum-free medium were placed in the top
chamber and incubated at 37°C for 24 h. Cells that had
migrated or invaded through the Matrigel on the bottom
surface of the filter were fixed with 4% paraformaldehyde
for 10 min and stained with 5% crystal violet (Sigma-
Aldrich) in 25% methanol for 10 min. Cells on the top
surface of the filter (cells that did not migrate or invade
through the Matrigel) were removed using a moist cotton
swab. Cells in 10 random fields were evaluated under × 400
magnification. The experiments were repeated thrice. Data
were expressed as the number of cells per area.
Endotube formation assay
We measured endotube formation by human umbilical
vein endothelial cells (HUVECs) using an angiogenesisassay on Matrigel (Growth Factor Reduced Matrigel
Matrix; BD Biosciences). To investigate the influence of
MUC4/Y overexpression on PANC-1 cell–HUVEC inter-
action on HUVEC endotube formation, we co-cultured
HUVECs with control and genetically modified PANC-1
cells using a double-chamber method in 24-well tissue
culture plates. Stable cell lines (1 × 105 cells) were seeded
into Transwell chambers consisting of polycarbonate
membranes with 0.4-mm pores (BD Biosciences) and
allowed to adhere overnight. To reconstitute the basement
membrane, Matrigel was diluted 2-fold with cold DMEM
(without FBS) and added to the plates (250 μL/well) at
4°C. Plates were incubated for 2 h in a 37°C cell culture
incubator to allow the Matrigel to solidify. HUVECs were
trypsinized, counted, resuspended in basal medium, and
added on top of the reconstituted basement membrane
(5 × 104 cells/well). The top chamber was then placed in
the HUVEC endotube formation assay system on Matrigel
as described above. Cells were incubated for 16 h to
allow tube formation. Endotubes were quantified by
counting five random fields from each sample under × 40
magnification.
Animals
Thirty-two female BALB/C nude mice were purchased
from the Nanjing University Model Animal Research
Center and housed in specific pathogen–free conditions.
This study was conducted in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Ministry of Health, China.
The Ethics Committee of the First Affiliated Hospital of
Nanjing Medical University (Permit Number: 2012-SRFA-
093) approved the protocol. The mice were randomly
assigned to four groups when they were 3–5 weeks old
and weighed 18–20 g: two groups each for subcutaneous
and orthotopic models. All surgery was conducted under
sodium pentobarbital anesthesia and all efforts were made
to minimize suffering.
Subcutaneous model and bioluminescence imaging
PANC-1–derived clones, i.e., PANC-1-MUC4/Y and
PANC-1-EV, were re-transfected with lentivirus (#pSB72;
ShangHai SBO Medical Biotechnology, CHINA) express-
ing both luciferase and green fluorescent protein (GFP).
GFP-expressing cells were sorted using a fluorescence-
activated cell sorter (FACS) and termed PANC-1-MUC4/
Y-Luc and PANC-1-EV-Luc (negative control), respect-
ively. Subconfluent cultures of PANC-1-MUC4/Y-Luc and
PANC-1-EV-Luc cells were trypsinized and washed with
PBS. Cell viability was determined by trypan blue staining;
single-cell suspensions with >90% viability were used for
the subcutaneous injections. Cells in 100-μL suspen-
sions (1 × 107) from each group of cells were injected
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luciferin (150 mg/kg in PBS; Promega) was used as the
substrate for the luciferase-expressing cells and injected
intravenously 1–2 minutes before imaging. Mice were
anesthetized using 3.5% chloral hydrate and imaged at
2 hours and 3, 10, 15, 21, 26, 30 days after tumor cell in-
jection and using a cooled charged-coupled device camera
(IVIS system; Xenogen). Exposure times for saturated im-
ages were reduced accordingly. Images were quantified as
photons/s using Living Image software (Xenogen). In vivo
tumor growth was monitored by measuring biolumines-
cence imaging (BLI). At 30 days after implantation, the
mice were sacrificed and the tumors harvested for paraffin
embedding and H&E staining, and immunohistochemical
(IHC) analysis.IHC, Ki67 staining, TUNEL, microvessel density assay
IHC staining was carried out using the standard avidin-
biotin complex method using Ki67 antibody (Dako, MIB-1,
1:200). Immune reactions were visualized with 3,3-diamino-
benzidine and counterstained with Mayer’s hematoxylin.
Ki67-positive cells were counted and presented as the aver-
age of the five highest areas within a single × 400 magnifica-
tion field. Terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL) was carried out using
an ApopTag Plus Peroxidase In Situ Apoptosis Detection
kit (Intergen) according to the manufacturer’s instruc-
tions. Briefly, slides were deparaffinized and treated with
20 μg/mL proteinase K at 37°C for 15 min to enhance
staining. After immersion in 3% hydrogen peroxide to
block endogenous peroxidase, slides were incubated
with reaction buffer containing terminal deoxynucleo-
tidyl transferase at 37°C for 1 h. The slides were then
incubated with peroxidase-conjugated anti-digoxigenin
antibody for 30 min, and the reaction products were
visualized with 0.03% 3,3-diaminobenzidine containing
2 mmol/L hydrogen peroxide. TUNEL-positive cells
were counted and presented as the average of the five
highest areas within a single × 200 field. To determine
microvessel density (MVD), 5-μm paraffin-embedded
sections were stained with rat anti-mouse CD31 mono-
clonal antibody (BD Biosciences). The average number
of CD31-positive vessels per field, denoting MVD, were
examined under × 100 magnification and counted.Orthotopic model metastasis assay
Cells (2 × 106, 50-μL suspensions) from PANC-1–derived
cell lines were orthotopically implanted in the pancreas of
nude mice as previously described [21]. The mice were
sacrificed at 45 days after implantation. The presence of
metastatic lesions in other organs was determined by
thorough gross inspection and histological analysis.Sequence-based digital gene expression analysis
Total RNA was extracted from three groups of cells:
PANC-1-MUC4/Y, wild-type PANC-1, and PANC-1-EV
using TRIzol (Invitrogen) according to the manufacturer’s
protocol. RNA integrity was confirmed using a 2100 Bioa-
nalyzer (Agilent Technologies). The samples intended for
transcriptome analysis were processed by BGI. Briefly,
6 μg total RNA was extracted, the mRNA purified using
oligo(dT) magnetic bead adsorption, and cDNA synthe-
sized using oligo(dT) as the primer. The 5′ ends of tags
can be generated using two endonucleases: NlaIII or
DpnII. Typically, the bead-bound cDNA is digested with
NlaIII, which recognizes and cuts off CATG sites. Frag-
ments other than the 3′ cDNA fragments connected to
the oligo(dT) beads are washed away and Illumina adaptor
1 is ligated to the sticky 5′ end of the digested, bead-
bound cDNA fragments. The junction of adaptor 1 and a
CATG site is the recognition site for MmeI, an endonucle-
ase with separate recognition and digestion sites. It cuts
17 bp downstream of the CATG site, producing tags with
adaptor 1. After removing the 3′ fragments with magnetic
bead precipitation, Illumina adaptor 2 is ligated to the 3′
ends of the tags, producing tags with different adaptors at
both ends to form a tag library. Following linear PCR
amplification, fragments are purified by polyacrylamide
gel electrophoresis. During the quality control steps, the
Agilent 2100 Bioanalyzer and Applied Biosystems
StepOnePlus Real-Time PCR System are used to quantify
and qualify the sample library, which is sequenced using
Illumina HiSeq 2000. The raw tag sequence data are
analyzed for gene annotation and normalization, screening
of differentially expressed genes (DEGs), and functional
annotation through the in-house bioinformatics analysis
pipeline.
DEG Gene Ontology functional enrichment and pathway
enrichment analysis
DEGs annotated against the Gene Ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) data-
bases were enriched to identify significant GO biological
process terms and pathways, respectively, and adjusted
with corrected P ≤0.05 for GO analysis and pathways.
Verification of DEGs and VEGF family molecules
Additional file 1: Table S2 lists the sequences of the
specific primer sets. The endogenous control gene (18S
rRNA) was used as an internal control. Quantitative RT-
PCR (qRT-PCR) was performed using a SYBR Premix Ex
Taq Kit (TaKaRa) according to the manufacturer’s proto-
col. A no-template control sample (nuclease-free water)
was included to detect contamination and to determine
the degree of dimer formation. Ct values were normal-
ized to the 18S gene and a relative quantitative method
(ΔΔCt) was used to evaluate quantitative variation. To
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sured up to three independent RNA samples per line.
cDNA was generated using an iScript cDNA Synthesis
Kit (Bio-Rad).
Additional file 1: Table S3 lists the sets of specific anti-
bodies and concentration used; we performed Western
blotting assays as described above.
To confirm the mechanism of MUC4/Y enhancement
of HUVEC endotube formation, we performed enzyme-
linked immunosorbent assay (ELISA) of vascular endo-
thelial growth factor (VEGF, main detection of VEGFA)
and interleukin-8 (IL8) in cell culture supernatants using
a kit as per the manufacturer’s instructions (R&D Systems).
We collected the supernatant from PANC-1-EV, and
PANC-1-MUC4/Y cell cultures. Cells (1 × 105/mL) were
seeded in a 24-well plate and cultured overnight. The
medium was replaced and cells were cultured for an-
other 24 h or 48 h. The culture media were collected
and microfuged at 1500 rpm for 5 min to remove parti-
cles, and the supernatant stored at −80°C until used in
the ELISA.Statistical analysis
Statistical analysis was performed using SPSS 17.0 (SPSS
Inc.). The results were confirmed by conducting at least
three independent experiments for all in vitro and in vivo
experiments.
Data obtained from patients and tissue specimens were
analyzed as described previously [10]. Data were analyzed
using the Mann–Whitney U test (or Kruskal–Wallis test).
All statistical tests were 2-tailed exact tests, with P <0.05
considered significant. Based on MUC4/Y expression level
cut-off values determined by receiver operating character-
istic (ROC) curve analysis, survival distributions were
estimated using the Kaplan–Meier method. Variables with
statistically significant prognostic value in univariate ana-
lyses were entered into a multivariate model and excluded
where P >0.10. Stepwise selection of factors was applied to
the multivariate Cox regression model to identify inde-
pendent prognostic factors for OS.
Between the two groups in the subcutaneous model,
the mean tumor growth rates of Luc-PANC-1 cells at dif-
ferent time points determined by BLI (photons/s) were
compared using repeated-measures analysis of variance
(ANOVA) to identify subject-by-time profiles.
Between the two groups in the orthotopic model, inci-
dence of metastasis was compared using Fisher’s exact test.
All data presented are the mean ± standard deviation
(SD) of n independent measurements unless noted
otherwise. Statistical analysis was performed with one-
way ANOVA for multiple groups and the unpaired Stu-
dent t-test for individual groups; statistical significance
was assigned when P <0.05.Results
MUC4/Y mRNA expression was significantly positively
correlated with tumor invasion, distant metastases and
MUC4 mRNA expression level
Figure 1 depicts the level of MUC4/Y expression normal-
ized to that of 18S rRNA. As shown in Table 1, The
Mann–Whitney U test (2-tailed exact tests) demonstrated
the level of tumor MUC4/Y expression was significantly
correlated with tumor-node-metastasis (TNM) stage
(P = 0.001), but no significant correlations were identi-
fied between the levels of tumor MUC4/Y expression
and other variables. TNM Staging System for pancre-
atic cancer were shown in Additional file 1: Table S1.
Here Stage IIB can be divided in two groups: one defined
as IIB-1, i.e. Tumor limited to the pancreas, Regional lymph
node metastasis, No distantant metastasis (T1 +T2, N1,
M0); the other defined as IIB-2, i.e. Tumor extends beyond
pancreas but locally invasive, Regional lymph node metasta-
sis, No distantant metastasis (T3, N1, M0). As shown in
Figure 1B, MUC4/Y expression at TNM stage IA + IB was
significantly lower than that at TNM stage IIA, IIB-2 or
III + IV (P = 0.012, 0.022, 0.001). MUC4/Y expression at
TNM stage IIA was significantly lower than that at TNM
stage III + IV (P = 0.012). MUC4/Y expression at TNM
stage IIB-1 was significantly lower than that at TNM stage
IIA, IIB-2 or III + IV (P = 0.004, 0.004, 0.000). MUC4/Y
expression at TNM stage IIB-2 was significantly lower
than that at TNM stage III + IV (P = 0.047). There was no
significant difference between MUC4/Y expression at
TNM stage IA + IB and IIB-1(P = 0.591). There was also
no significant difference between MUC4/Y expression at
TNM stage IIA and IIB-2 (P = 0.752).
We quantified the correlation between MUC4/Y and
MUC4 expression levels in pancreatic cancer tissues
with real-time PCR. Figure 1C depicts a positive correl-
ation between MUC4/Y and MUC4 expression levels in
PDAC (R2 = 0.430, P <0.001).Association between MUC4/Y mRNA expression levels, or
clinicopathological factors and PDAC patient survival
We enrolled 108 PDAC patients in the survival analysis.
Eighty-four patients died; the remaining 24 patients were
alive at the last follow-up (May 31, 2013). The OS rates
at 12, 18, and 24 months were 37.96%, 21.30%, and
15.74%, respectively. Patients were divided into two
groups based on the length of OS: short-term survivors
(survival <24 months) and long-term survivors (sur-
vival ≥24 months).
The threshold value of 0.0044 was chosen as the cut-
off score for both high and low MUC4/Y expression, as
0.0044 (within the MUC4/Y expression 95% confidence
interval [CI] of 0.0043-0.0150) was on the ROC curve
closest to (0.0, 1.0). This maximized both sensitivity and
Table 1 Clinicopathological factors and the expression of MUC4/Y in 108 patients with PDAC
Category N(%) MUC4/Y
Mean Median(range) P Value
Age(y)
<60 47 (43.52) 0.0076 0.0010(0.0000-0.0829) 0.689
≥60 61 (56.48) 0.0112 0.0012(0.0000-0.2350)
Gender
Male 61 (56.48) 0.0117 0.0013(0.0000-0.2350) 0.228
Female 47 (43.52) 0.0070 0.0010(0.0000-0.0787)
Location of tumor
Head 72 (66.67) 0.0071 0.0010(0.0000-0.0842) 0.494
Body and tail 36 (33.33) 0.0147 0.0015(0.0000-0.2350)
Size of tumor
≤2 cm 22 (20.37) 0.0074 0.0010(0.0000-0.0682) 0.647
>2 cm 86 (79.63) 0.0102 0.0011(0.0000-0.2350)
Nerve infiltration
No 38 (35.19) 0.0098 0.0007(0.0000-0.0842) 0.137
Yes 70 (64.81) 0.0096 0.0012(0.0000-0.2350)
Differentiation
Well 15 (13.89) 0.0267 0.0012(0.0000-0.2350) 0.979
Moderate 83 (76.85) 0.0071 0.0011(0.0000-0.0842)
Poor 10 (9.26) 0.0055 0.0011(0.0001-0.0340)
TNMa staging
IA + IB 15 (13.89) 0.0009 0.0006(0.0000-0.0040) 0.001*
IIA 33 (30.56) 0.0056 0.0015(0.0001-0.0682)
IIB 46 (42.59) 0.0069 0.0008(0.0000-0.0842)
III + IV 14 (12.96) 0.0380 0.0076(0.0003-0.2350)
Serum CA19-9b level
≤39KU/l 31 (28.70) 0.0155 0.0009(0.0000-0.2350) 0.965
>39KU/l 77 (71.30) 0.0073 0.0011(0.0000-0.8423)
Serum CA50c level
≤25KU/l 49 (45.37) 0.0152 0.0009 (0.0000-0.2350) 0.894
>25KU/l 59 (54.63) 0.0050 0.0011(0.0000-0.0829)
Serum CEAd level
≤5 μg/l 64 (59.26) 0.0093 0.0010(0.0000-0.0842) 0.557
>5 μg/l 44 (40.74) 0.0101 0.0011(0.0000-0.2350)
TNMa, tumor-node-metastasis; CA19-9b, carbohydrate antigen 19–9; CA50c, carbohydrate antigen 50; CEAd, carcinoembryonic antigen; *P <0.05.
Zhu et al. Journal of Translational Medicine 2014, 12:309 Page 8 of 23
http://www.translational-medicine.com/content/12/1/309specificity for survival outcome. The area under the
ROC curve was 0.861 (95% CI: 0.784-0.938, P = 0.000).
The Kaplan–Meier survival curves showed that post-
operative survival was shorter for patients with high
(≥0.0044) MUC4/Y expression compared to patients
with low (<0.0044) expression (P = 0.002, log rank test;
Figure 1D).
As shown in Figure 2, the survival of patients with
tumors occurring in the body or tail of the pancreas,
poor tumor differentiation, TNM staging of III + IV, high
serum (>39 kU/L) of CA19-9, high serum (>5 μg/L) ofCEA, high (≥0.056) MUC4/Y expression was signifi-
cantly worse than those with tumors occurring in the
head of the pancreas(P = 0.020, log rank test), well and
moderate tumor differentiation (P<0.001, log rank test),
TNM staging of A + IB or IIA or IIB (P = 0.003, log rank
test), low serum level of CA19-9(P = 0.009, log rank test),
low serum level of CEA(P = 0.025, log rank test), low
MUC4/Y expression(P<0.001, log rank test), respectively.
There were no significant associations between survival
and patient gender, age, tumor size, nerve infiltration
(P = 0.489, 0.173, 0.340, 0.689, respectively; log rank test).
Figure 2 Kaplan-Meier survival estimate by clinicopathological factors for 108 PDAC patients who underwent pancreaticoduodenectomy
and survived at least 30 days after surgery. The p value was calculated by the Log-rank test. The correlation between survival and tumor location
(A), tumor differentiation (B), TNM staging (C), serum level of CA19-9 (D), serum level of CA50 (E), serum level of CEA (F), MUC4 mRNA expression
status (G), respectively, among which the P value of serum level of CA50 lied in the critical (P = 0.054).
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CA50 lied in the critical (P = 0.054).
Using P = 0.10 as the cut-off value, eight factors
(tumor location, tumor differentiation, TNM stage,
serum carbohydrate antigen [CA]19-9, serum CA50,
serum carcinoembryonic antigen, MUC4 expression, and
MUC4/Y expression) were selected from the univariate
analysis data (Table 2) for forward or backward stepwise
multivariate Cox proportional hazard analysis (Table 3).
Forward stepwise multivariate Cox analysis determined
that tumor differentiation (P = 0.001; hazard ratio [HR],
moderate: 2.368, 95% CI: 1.120-5.007; HR, poor: 6.603,
95% CI: 2.515-17.338), serum CA19-9 (P = 0.021; HR:
1.914, 95% CI: 1.105-3.318), and MUC4 expression
(P= 0.001; HR: 2.281, 95% CI: 1.415-3.677) were significantindependent risk factors. Backward stepwise multivariate
Cox analysis determined that tumor location (P = 0.001;
HR: 2.452, 95% CI: 1.414-4.253), tumor differentiation
(P <0.001; HR, moderate: 2.163, 95% CI: 0.994-4.706; HR,
poor: 7.076, 95% CI: 2.655-18.857), TNM stage (P = 0.014;
HR, IIA: 3.395, 95% CI: 1.414-8.148; HR, IIB: 3.551, 95%
CI: 1.523-8.277; HR, III + IV: 4.218, 95% CI: 1.652-10.768),
serum CA19-9 (P = 0.008; HR: 2.817, 95% CI: 1.313-
6.043), and MUC4 expression (P = 0.010; HR: 1.976, 95%
CI: 1.174-3.326) were significant independent risk factors.
MUC4/Y stable overexpression
To investigate the role of MUC4/Y in pancreatic cancer,
PANC-1 cells, which do not express endogenous MUC4
[22], were infected with viral supernatant containing
Table 2 Univariate analysis of prognostic factors
Variable Cases Events Mean survival (months) HRa (95% CIb) p
Gender 0.504
Male 61 47 16.176 1
Female 47 37 19.699 0.862 (0.559-1.331)
Age (y) 0.176
< 60 47 35 21.381 1
≥ 60 61 49 15.254 1.352 (0.874-2.092)
Location of tumor 0.026*
Head 72 52 20.770 1
Body and tail 36 32 12.235 1.655 (1.062-2.579)
Size of tumor (cm) 0.358
≤ 2 22 67 20.116 1
>2 86 17 17.290 1.285 (0.753-2.192)
Differentiation <0.001*
Well 15 8 34.953 1
Moderate 83 66 15.803 2.532 (1.202-5.332) 0.015*
Poor 10 10 5.700 7.624 (2.918-19.916) <0.001*
Nerve infiltration 0.699
No 38 29 21.137 1
Yes 70 55 16.406 1.094 (0.694-1.725)
TNM staging 0.007*
IA + IB 15 12 24.448 1
IIA 33 25 17.483 1.371 (0.684-2.751) 0.374
IIB 46 34 18.785 1.507 (0.777-2.925) 0.225
III + IV 14 13 6.982 3.729 (1.664-8.358)) 0.001*
Serum CA19-9 (kU/L) 0.014*
≤ 39 31 16 28.993 1
> 39 77 68 14.556 1.988 (1.150-3.436)
Serum CA50 (kU/L) 0.065*
≤ 25 49 30 24.091 1
> 25 59 54 14.459 1.529 (0.975-2.398)
Serum CEA (μg/L) 0.032*
≤ 5 64 44 22.116 1
> 5 44 40 12.072 1.609 (1.041-2.488)
MUC4 (2-ΔCt) <0.001*
Low (<0.056) 75 54 22.101 1
High (≥0.056) 33 30 8.054 2.595 (1.612-4.179)
MUC4/Y (2-ΔCt) 0.003*
Low (<0.0044) 79 58 21.126 1
High (≥0.0044) 29 26 8.835 2.077 (1.283-3.365)
aHR, hazard ratio; bCI, confidence interval; *P ≤ 0.10.
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for effective MUC4/Y overexpression or to serve as con-
trols, respectively. Pooled populations of Puro-tagged
stable transfected sub-lines were selected using 10%
DMEM containing puromycin (2.0 μg/mL).We examined stable MUC4/Y overexpression in PANC-
1-MUC4/Y cells at transcript and protein level using real-
time PCR and immunoblotting, respectively; the negative
and blank controls were mock-transfected cells (PANC-
1-EV) and parental wild-type PANC-1 cells, respectively.
Table 3 Multivariate analysis of prognostic factors
Variable Forward stepwise Backward stepwise
HRa (95% CIb) p HR (95% CI) p
Location of tumor 0.085 0.001*
Head - 1
Body and tail - 2.452 (1.414-4.253)
Differentiation 0.001* <0.001*
Well 1 1
Moderate 2.368 (1.120-5.007) 0.024* 2.163 (0.994-4.706) 0.052
Poor 6.603 (2.515-17.338) <0.001* 7.076 (2.655-18.857) <0.001*
TNM staging 0.175 0.014*
IA + IB - 1
IIA - 0.929 3.395 (1.414-8.148) 0.006*
IIB - 0.922 3.551 (1.523-8.277) 0.003*
III + IV - 0.077 4.218 (1.652-10.768) 0.003*
Serum CA19-9 (kU/L) 0.021* 0.008*
≤ 39 1 1
> 39 1.914 (1.105-3.318) 2.817 (1.313-6.043)
Serum CA50 (kU/L) 0.535 0.085
≤ 25 - 1
> 25 - 0.552 (0.280-1.086)
Serum CEA (μg/L) 0.265 0.089
≤ 4.3 - 1
> 4.3 - 1.554 (0.934-2.584)
MUC4 (2-ΔCt) 0.001* 0.010*
Low (<0.056) 1 1
High (≥0.056) 2.281 (1.415-3.677) 1.976 (1.174-3.326)
MUC4/Y (2-ΔCt) 0.067 0.243
Low (<0.0044) - -
High (≥0.0044) - -
aHR, hazard ratio; bCI, confidence interval; *p <0.05.
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RT-PCR with gene-specific priming (Figure 1A). The
level of MUC4/Y mRNA expression was normalized to
that of 18S rRNA. MUC4/Y expression in PANC-1-
MUC4/Y cells was 9912-fold and 9808-fold higher than
that in the blank and negative controls, respectively
(Figure 3A).
In agreement with the mRNA findings, western blot-
ting confirmed MUC4/Y overexpression in the PANC-
1-MUC4/Y cells. The selected monoclonal antibody
(#ab60720; Abcam) is specifically directed against amino
acids 79–189 of human MUC4, which are included in the
protein expressed by the MUC4/Y target gene. Figure 3B
depicts a band that had migrated a distance consistent
with the expected 133-kDa molecular weight of MUC4/Y.
The blank and negative control cells were negative
for MUC4 expression. HPAC, a MUC4-overexpressingpancreatic cell line, was used as a positive control for
specific antibody [13].
We used the MUC4 monoclonal antibody to examine
the subcellular localization of MUC4/Y using immuno-
fluorescence. The pancreatic cancer cell line BXPC-3 is
MUC4 positive-expression as positive control [13]. In
BXPC-3 cells, there was both membranous and cytoplasmic
staining for MUC4 (Figure 3C). A similar distribution was
observed for PANC-1-MUC4/Y cells. MUC4/Y and wild-
type MUC4 had similar sub-cellular localization, indicating
similar MUC4 and MUC4/Y processing in the cells.
MUC4/Y contributed to enhance proliferation under low-
nutritional-pressure, anti-apoptosis, motility, invasiveness,
and HUVEC endotube formation in PANC-1 cells in vitro
Figure 4A shows that there was no significant difference
for PANC-1-MUC4/Y cells grown in 10% serum compared
Figure 3 MUC4/Y expression and subcellular localization in PANC-1 cells. (A) Real-time PCR using specific primers and TaqMan probe to
examine MUC4/Y transcript expression in PANC-1-EV cells and PANC-1-MUC4/Y cells. The level of target gene expression in the PANC-1-MUC4/Y
cells was 9912-fold and 9808-fold higher than that of the blank control and negative control, respectively. (B) Western blot confirmation of
MUC4/Y protein expression. Total protein from cell extracts was resolved on precast gels. The signal was detected using an electrochemiluminescence
reagent kit. (C) Immunofluorescence demonstrating MUC4/Y subcellular localization similar to that of wild-type MUC4. The pancreatic cancer cell lines
of HPAC and BXPC-3 is MUC4 positive-expression as positive control for specific antibody.
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Figure 4 MUC4/Y enhances PANC-1 cell malignant activity in vitro. Data from three repeated experiments are presented as means ± SD.
**P <0.01, ***P <0.001 vs. controls. (A) MUC4/Y enhanced in vitro proliferation of PANC-1 cells under stress from low nutritional status. The absorbance
values of cells at different time points were detected with WST-8 dye. Cells were maintained in medium containing 10% serum (left) and 1%
serum (right). (B) MUC4/Y increased resistance to apoptotic reagents, i.e., sorafenib. Representative templates of FACS analysis showing the
proportion of cells positive for annexin V and 7-AAD (top right quadrant) representing the percentage of necrotic cells; the proportion of cells
that were annexin V–positive and 7-AAD–negative (bottom right quadrant) represented the percentage of apoptotic cells (top). Bar denotes the
percentage of apoptotic and necrotic cells in PANC-1–derived clones (bottom). (C) MUC4/Y affected pancreatic cancer cell metastatic potential
in vitro. Bar graph shows the number of PANC-1–derived clones that had migrated or invaded through the Matrigel. (D) MUC4/Y enhanced cancer
cell–associated HUVEC endotube formation. Bar denotes the fold increase of the number of endotubes compared to the blank control.
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status (1% serum), there were significant increases in
the proliferation of PANC-1-MUC4/Y cells compared to
the blank controls at 96 h and 120 h (P = 0.003, 0.000,
respectively), suggesting that MUC4/Y enhances in vitro
proliferation of PANC-1 cells under stress from low
nutritional status.
To examine whether MUC4/Y enhances resistance to
apoptosis in pancreatic cancer cells, PANC-1-MUC4/Y
cells and the controls were treated with 8 μM sorafenib
for 24 h and apoptosis was assessed using flow cytome-
try. The proportion of cells positive for annexin V and 7-
AAD was significantly decreased (P <0.01, respectively)
compared to the blank and negative controls (Figure 4B),
suggesting that MUC4/Y plays an anti-apoptotic role in
pancreatic cancer in vitro.
We used Transwells without or with Matrigel-coated
membranes to examine cell migration and invasion,
respectively, in vitro. The average number of migrating
cells indicated the significantly increased migration abil-
ity of PANC-1-MUC4/Y cells compared to that of the
controls (P <0.01, respectively). Figure 4C shows that the
number of PANC-1-MUC4/Y cells invading through the
Matrigel was significantly higher than that of the con-
trols (P <0.001, respectively). These data suggest that
MUC4/Y can affect the metastatic potential of pancreatic
cancer cells in vitro.
We also investigated whether MUC4/Y modulates the
ability of PANC-1 cells to influence endotube formation
by vascular endothelial cells. We used a 2-chamber co-
culture system to demonstrate the interaction between
PANC-1 cells and HUVECs. Co-culturing HUVECs with
PANC-1-MUC4/Y cells significantly enhanced HUVEC
endotube formation (P <0.01) compared to co-culture
with the negative and blank controls (Figure 4D).
MUC4/Y contributed to increase tumor growth and
metastasis with rising proliferative activity, MVD, and
metastasis incidence and decreased apoptosis in vivo
To analyze the role of MUC4/Y in vivo, we developed
subcutaneous and orthotopic models using PANC-1–
derived clones.
In the subcutaneous model, we used PANC-1-MUC4/
Y-Luc cells (negative control: PANC-1-EV-Luc) to obtain
in vivo BLI, and the mean tumor growth rates at differ-
ent time points determined by BLI (photons/s) were
compared using repeated-measures analysis of variance
(ANOVA) to identify subject-by-time profiles. Subcuta-
neously localized luciferase activity was identical in the
two groups at the 2-hour time point, but at the 26, 30-
day time point, there was a statistically significant in-
crease in the bioluminescent signal in PANC-1-MUC4/
Y-Luc cells compared to the negative control (Figure 5A),
indicating that at the later stages, significant differenceof tumor growth arised due to MUC4/Y-overexpression
in vivo.
Moreover, at the 30-day time point, mice were sacrificed,
and tumor sizes were measured. There was significant dif-
ference in tumor size between the two groups (Figure 5B,
P <0.05).
Ki-67 is an excellent marker of cell proliferation. Histo-
logic evaluation of the tumors confirmed that MUC4/
Y-overexpression markedly increased the fraction of Ki-67-
positive tumor cells (the Ki-67 labelling index) compared to
the controls (P <0.05, Figure 5C, the Second Line).
TUNEL was performed to assess the number of apop-
totic cells in vivo. The proportion of TUNEL-positive
PANC-1-MUC4/Y-Luc cells was significantly lower com-
pared to the controls (P <0.05, Figure 5C, the Third Line).
We also assessed the effects of MUC4/Y overexpres-
sion on tumor vasculature by MVD analysis via CD31
staining of tumors vasculature (Figure 5C, the Fourth
Line). Compared to the controls, MUC4/Y significantly
increased MVD in the subcutaneous tumors (P <0.05).
Given the importance of the microenvironment in
cancer pathogenesis, we developed a pancreatic orthoto-
pic model to observe metastasis using PANC-1–derived
clones with or without MUC4/Y overexpression. We
confirmed metastasis by visual and histological inspec-
tion (Figure 6A-B). We also used in vivo BLI to confirm
that the metastases were not related to tumor cell spill-
age at the time of orthotopic implantation (Figure 6A-2).
The overall tumor incidence between the two groups
was not significantly different. However, there were
higher incidences of metastasis at different sites in the
MUC4/Y-overexpressing group compared to the control
groups (Figure 6C), including tumor spread in the spleen
(6/8 vs. 4/7, P = 0.608), liver (7/8 vs. 3/7, P = 0.119),
peritoneum (5/8 vs. 3/7, P = 0.619), mesenteric lymph
nodes (5/8 vs. 2/7, P = 0.315), diaphragm (2/8 vs. 1/7, P =
1.000), intestinal wall (4/8 vs. 0/7, P = 0.026), and lung
(6/8 vs. 1/7, P = 0.041), suggesting that MUC4/Y overex-
pression promoted tumor metastasis (intestinal wall) and
distant metastasis (lung) significantly effectively. Vein
tumor thrombi were obvious in the PANC-1-MUC4/Y
group (Figure 6B-6), suggesting that MUC4/Y overexpres-
sion aids in PANC-1 cell hematogenous metastasis.
In sum, the above-mentioned data confirmed that the
overexpression-MUC4-Y resulted in increasing tumor
growth and metastasis in vivo.
DEG screening and functional annotation for global
mRNA analysis of PANC-1-MUC4/Y- cells
Using DGE analysis, we compared PANC-1-MUC4/Y
cells to the blank and negative controls to identify the
overlapping differential genes based on re-sampling tests
and elimination of negative vector and random insert
effects. Comparative analyses of MUC4/Y-associated
Figure 5 MUC4/Y contributed to increase tumor growth with rising proliferative activity and MVD and decreased apoptosis in vivo.
(A) In vivo BLI showing the tumor growth rates over time in the subcutaneous model. Up: Representative luminescence images for each group.
Down: Tumor growth rates indicated by bioluminescence (photons/s) in PANC-1-MUC4/Y-Luc (n = 6) and control (n = 6) BALB/c nude mice at
2 hours and 3, 10, 15, 21, 26, 30 days after tumor cell injection; bars, SE. *P <0.05, ***P <0.001. (B) Subcutaneous tumors and their size (mm) from
two groups measured at the 30-day time point when mice were sacrificed. Scatter dot, tumor size of every mouse; the center horizontal line,
mean. *P <0.05. (C) Histological and IHC analysis of subcutaneous tumors. Histologically, there was no difference between subcutaneous tumors
of the PANC-1-MUC4/Y-Luc group and control groups (H&E staining, ×400 magnification). Ki67, TUNEL, and CD31 staining is of paraffin-
embedded sections from solid tumors. Micrographs are representative images of two groups (Ki67, TUNEL, CD31: ×400, 200, 100 magnification,
respectively). Charts depict the mean proportion of Ki67- and TUNEL-positive cells and the average number of CD31-positive microvessels per
field, respectively. Five fields per slide and at least five slides per group were examined and compared using the Student t-test. Columns, mean;
bars, SD; *P <0.05.
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the blank and negative control cell lines, respectively,
including 1575 overlapping genes [see Additional file 1:
Table S4 lists the DEGs, intersection set of PANC-1-
MUC4/Y compared to the controls, respectively, abso-
lute value of log2 ratio ≥1].
To understand the DEG global functions, we carried
out enrichment analysis of GO function [23] and the
KEGG pathway [24]. Additional file 1: Table S5 lists the
detailed results of the GO enrichment analysis, indicat-
ing that MUC4/Y overexpression not only resulted in
transcriptional change of the transmembrane, which is
intrinsic to membrane and extracellular region–associ-
ated proteins for cytokine activities that control tissue
and cell survival, growth, differentiation, and effector
function, but also altered interactions between the celland its surroundings, and intracellular signaling and
signal transmission.
Enrichment analysis with KEGG confirmed that the
set of 1575 DEGs was enriched for pathways not only
correlated to cancer, but also were associated with
MUC4, as shown in the literature database (Additional
file 1: Table S6), and was consistent with the GO func-
tional enrichment analysis.Verification of DEGs related with the malignant functions
of MUC4/Y and VEGF family molecules
To evaluate the malignant functions of MUC4/Y, we sum-
marized the distribution of DEGs in a number of pathways
markedly related to the malignance of cancer using
Database for Annotation, Visualization, and Integrated
Figure 6 (See legend on next page.)
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Figure 6 Development of orthotopic pancreatic cancer model for observation of metastasis. (A) Development of orthotopic pancreatic
cancer and gross inspection. 1. PANC-1–derived clones were orthotopically implanted in the parenchyma of the pancreatic head. 2. Luciferase activity
imaging at two days following tumor cell injection confirming orthotopic implantation at the injection site without cell spillage. 3–8. Metastasis to the
peritoneum, peritoneum and liver, liver, diaphragm and liver, mesenteric lymph node and intestinal wall, and lung, indicated by arrowheads (▲), were
obvious macroscopically. (B) Histological analysis of metastatic lesions. Metastatic lesions of the spleen, liver, downward mucosa of the intestine,
intestinal wall, lung, vein tumor thrombi (H&E staining, left: ×100 magnification; right: ×200 magnification, Δ indicates tumor). (C) Increased incidences
of metastasis at different sites in MUC4/Y overexpression group compared to the control group (n = 8 per group). Comparisons between groups were
tested with the chi-square test, *P <0.05.
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tions (Figure 7A).
For qPCR validation, we selected a batch of DEG mol-
ecules that play roles in the main pathways related to
oncogenic transformation, based on the literature data-
base. The independent qRT-PCR results for these genes
were consistent with the DGE results (Figure 7B), indi-
cating that our sequencing approach and analytical
pipeline were reliable.
For western blotting, we selected a batch of proteins
related to DEG molecules, especially protein phosphoryl-
ation (Figure 7C). There was a MUC4/Y-dependent in-
crease of ErbB2 phosphorylation activation, paralleled by
the upregulation of key molecules (Ras, Src, focal adhe-
sion kinase [FAK], extracellular signal–regulated kinase
[ERK], c-Jun amino-terminal kinase [JNK], AKT, nuclear
factor κB [NFκB], inhibitor of NFκB [IκBα], c-Jun), as ei-
ther total or phosphorylated proteins, in the downstream
signaling pathways.
Based on the results demonstrating the effect of
MUC4/Y associated with angiogenesis and metastasis in
malignant progression of pancreatic cancer, we verified
the expression change of the key factors in cell culture
supernatants with ELISA, combined with validation of
their mRNA expression by qRT-PCR. MUC4/Y overex-
pression up-regulated the transcriptional level of VEGFA
and VEGFB compared to the control, but down-regulated
VEGFC transcriptional level (Figure 7B). MUC4/Y overex-
pression significantly increased PANC-1-MUC4/Y cell
output of both VEGF (main detection of VEGFA) and
IL8/CXCL8 into the medium after 24-h or 48-h incuba-
tion compared to the control (Figure 7D).
Discussion
We designed specific primers and a TaqMan probe
(Figure 1A) for MUC4/Y and verified their specificity
by sequencing the PCR products. We applied a strict
statistical test which found that with the rise in levels
of TNM stage, the level of MUC4/Y mRNA expression
increased significantly. MUC4/Y expression at TNM
stage IA + IB was significantly lower than that at TNM
stage IIA, IIB-2 or III + IV, and its expression at IIA,
IIB (including IIB-1,2) was significantly lower than that
at III + IV, respectively. These suggest that MUC4/Yrelates to the invasion, progression and distant metastases,
which also coincides with the results of in vitro and
in vivo experiments based on stable MUC4/Y-overex-
pressing pancreatic cancer cell models. The single discrep-
ancy that we observed in the staging system is relatively
minor. There is no significant difference between MUC4/
Y expression at TNM stage IA + IB and IIB-1(regional
nodal involvement), and there was also no significant dif-
ference between MUC4/Y expression at TNM stage IIA
and IIB-2 (regional nodal involvement). This may be be-
cause of the level of MUC4/Y mRNA expression is not as-
sociated with regional lymph node metastasis. The results
of positive correlation between MUC4/Y and MUC4 ex-
pression levels in PDAC clinical samples also suggest that
MUC4/Y might play similar roles as MUC4 in the malig-
nant progression of PDAC patient.
Every univariate factor-specific overall survival was
estimated by using the Kaplan-Meier method and com-
pared with log-rank tests. Our results showed those
variables identified by the Kaplan-Meier method as hav-
ing predictive value were the same ones as by univariate
analysis (Figure 2 and Table 2), which would be included
in the multivariate analysis. Then the effect of potential
confounding variables on survival was examined by using
the multivariate Cox proportional hazard model after
adjusting for confounding, including global and covariate-
specific tests. Our results showed that as same as tumor
location, tumor differentiation, TNM staging, serum level
of CA19-9, serum level of CA50, serum level of CEA and
MUC4 mRNA expression status, MUC4/Y mRNA ex-
pression level was also significant predictor of survival
in univariate analysis. But only tumor location, tumor
differentiation, TNM stage, serum CA19-9, and MUC4
expression were independently associated with survival
differences in a multivariate Cox proportional hazards
model, which are in accordance with previous reports
[10,11,25,26]. These results suggest that the effect of
MUC4/Y expression is less than the effect of MUC4
expression on survival. That might be because MUC4/Y is
only the one of splice variants of MUC4.
Using lentiviral transfection, we constructed and identi-
fied pancreatic cancer PANC-1 cell lines that stably over-
expressed the MUC4/Y gene. The subcellular localization
is similar to that of wild-type MUC4, indicating that all
Figure 7 qRT-PCR, western blotting, and ELISA verification of DEGs related to the malignant functions of MUC4/Y and VEGF family
molecules. (A) Distribution of DEGs in the main pathways related to oncogenic transformation showing the change derived from MUC4/Y
overexpression–associated molecular signatures; the proportions of each pathway (represented by different colors) are graphed. The DEG list for
annotations is the intersection set of PANC-1-MUC4/Y compared to the controls; absolute value of log2 ratio ≥1. (B) Representative qPCR
validation results of 44 DEGs and VEGF family molecules (VEGFA, B, C) in PANC-1-MUC4/Y and control cell. (C) Western blot analysis verified a
significant upregulation of t-HER2/ErbB2, p-HER2/ErbB2, t-FAK, p-FAK, p-Src, p-AKT(Thr308), p-AKT(Ser473), p-IκBα, p-NF-kB, t-ERK, p-ERK, t-JNK, p-JNK,
and p-C-JUN in PANC-1-MUC4/Y compared with control. (D) ELISA of VEGF and IL8/CXCL8 using cell culture supernatants. Left: VEGF; right: IL8/CXCL8
production from PANC-1–derived clones incubated for 24 h or 48 h. Bars denote mean ± SD, ***P <0.001, **P <0.01.
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in our MUC4/Y-overexpressing cell model in agreement
with that of wild-type MUC4. Based on the cell models,
our results reveal that MUC4/Y contributes to enhance
malignant activities that were observed in the experimental
assay in vitro and in vivo, including proliferation, evasion
or resistance to apoptosis, angiogenesis and metastasis.
Meanwhile, We noted that MUC4/Y enhanced in vitro
proliferation of PANC-1 cells under stress from lownutritional status. Coincidentally, bioluminescence im-
aging revealed that MUC4/Y contributed to enhance the
tumor growth rates in the subcutaneous model at the
later stages (day26, 30 after injection). We speculate
that MUC4/Y may be initiate survival signals, increase
energy-generating ability or prevent the apoptosis to resist
the stress from the lack of growth factors and energies.
Additionally, the differences of growth rates between
MUC4/Y-overexpressed PANC-1 cells and control in
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tumors not growing large enough to undergo an angio-
genic switch. Furthermore, the detailed analyses of
transcriptome changes caused by MUC4/Y gene sup-
port this inference. MUC4/Y not only up-regulates a
series of genes (GLI family zinc finger 3, GLI3 [27];
bone morphogenetic protein 2, BMP2 [28]; wingless-
type MMTV integration site family member 10B,
WNT10B [29], IL8 [30], NGF [31]) related to the en-
hancement of cancer cell proliferation and increased
transcription of apoptotic protein inhibitors (baculoviral
IAP repeat containing 7, BIRC7 [32];), but also up-
regulates glucose transporter (SLC2A1/GLUT1) related to
the increased energy-generating ability.
We developed a pancreatic orthotopic model to observe
tumor spontaneous metastases by visual and histological
inspection. Tumors developed at organ sites similarly as
metastatic colonization by human PDAC metastases, in-
cluding direct invasion to adjacent organs (spleen, intes-
tine, peritoneum), regional lymph node metastases or
dissemination by those (mesenteric lymph nodes, dia-
phragm), and distant metastasis (liver, lung). Our data
indicate that MUC4/Y overexpression promoted adja-
cent metastasis (intestinal wall) and distant metastasis
(lung) significantly effectively, which also is consistent
with the positive correlation of MUC4/Y mRNA expres-
sion with tumor invasion and distant metastases in
human PDAC clinic samples. Additionally, the effects of
MUC4/Y on ascending malignant abilities(proliferation,
anti-apoptosis, motility, invasiveness, angiogenesis) of
tumor cells can also affect the metastatic potential of
pancreatic cancer cells during multi-steps of metastasis
process, including invasion, intravasation, extravasation,
metastatic colonization. Notably, our data provide evidence
for MUC4/Y upregulates ITGB8 downstream of the actin
cytoskeleton pathway (ITGB8-FAK-Cas/CrkII/DOCK180
complex-RAC- IRSp53- WAVE2-Arp2/3-F-Actin/PFN
complex) to affect actin dynamics and cancer cell
motility [33].
Angiogenesis is critical for the continuous growth of
tumors and the development of metastases. Our study
provides evidence that MUC4/Y plays an initial role in
tumor angiogenesis. We find and verify that MUC4/Y
overexpression contributed to an array of crucial factors
involved in angiogenesis: IL8 [34], CXCL3, CXCL5 [35],
matrix metalloproteinase (MMP)11 [36], MMP25 [37],
MMP28 [38], VEGF [39]. Interestingly, MUC4/Y up-
regulates the transcriptional level of VEGFA and VEGFB,
but down-regulates VEGFC transcriptional level compared
to the control. VEGF represents a family with multiple
functions that affect tumor growth and metastasis. Specif-
ically, VEGF-A is crucial for tumor angiogenesis and plays
a key role in endothelial cell growth, migrationl, and per-
meability as a ligand for VEGFR-1 and VEGFR-2. VEGFBregulates the formation of blood vessels and are involved
in endothelial cell physiology as a ligand for VEGFR-1 and
NRP-1(neuropilin-1). The up-regulation of both of the
above explains MUC4/Y contributes to tumor angiogen-
esis. The other isoform of VEGF, VEGFC and its specific
receptor VEGFR-3 compose an essential signal pathway
for lymphatic vessel growth in physiological and patho-
logical conditions, more importantly in lymphatic spread
of metastases. Intriguingly, the down-regulation of VEGFC
coincides with MUC4/Y has no effect on regional lymph
node metastases in pancreatic orthotopic model- mice and
PDAC clinic samples, although more experiments may
need to be confirmed.
Significantly, as shown in Figure 8, we investigated tran-
scriptome changes caused by MUC4/Y expression using
DGE technology, bioinformatics analysis and experimental
verification, and have depicted a condensed version focus-
ing on the malignant activity related pathways.
Importantly, we have found that EGF domain in MUC4/
Y and its interaction with ErbB2 and ErbB3 receptors trig-
ger intrinsic protein–tyrosine kinase activity and further
activate intracellular signaling pathways (e.g., mitogen-
activated protein kinase [MAPK], phosphatidylinositol-
3-kinase [PI3K]–Akt, protein kinase C [PKC] pathways),
and coactivate transcription of the downstream effector
molecules to mediate malignant functions of tumor cell,
specifically, the production or upregulation of cytokines,
growth factors, extracellular matrix (ECM), integrins
(ITGs), and corresponding membrane receptors (CXCL3/
5/8, nerve growth factor [NGF], neurotrophic tyrosine
receptor kinase type 1 [NTRK1], platelet-derived growth
factor beta polypeptide [PDGFB], fibroblast growth factor
[FGF]5/11, FGFR4, collagen triple helix repeat-containing
1 [CTHRC1], laminin alpha 4 [LAMA4], ITGB8; range:
1.27 ± 0.20-fold to 27.92 ± 3.58-fold increase). Notably, the
transcription of cytokines, growth factors, ECM, and
ITGs, and the interaction between them and the corre-
sponding membrane receptors can in turn lead to upregu-
lation of the signal transduction cascades, including the
MAPK, PI3K–Akt, and PKC pathways. Thus, MUC4/Y
expression that concomitantly elicits transcript-level up-
regulation of an array of molecules creates the positive
feedback regulatory loops that would result in sus-
tained upregulation of oncogenetic and progression
signaling and lead to complex interplay or crosstalk
between several signaling pathways.
Significantly, the above analysis and the novel finding
that MUC4/Y triggers positive feedback loops related to
malignant activity not only suggest that tumor cells can
engage MUC4/Y to express survival factors concomitantly
to resist adverse conditions in the microenvironment, e.g.,
in the circulatory systems during metastasis, but also sug-
gest that tumor cells can exploit MUC4/Y expression to
affect the tumor milieu by increasing the expression of
Figure 8 MUC4/Y-dependent pathways involved in malignant activity. Scheme depicts gene complexes and families (hexagons), membrane
receptors (rectangles), function (hollow cylinders), and others (ovals). Red, purple, and blue key factors in the signaling pathways were verified by
qRT-PCR, western blotting, and ELISA, respectively. Red lines denote the triggers.
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although the lack of the TR domain mainly relates to
cell–ECM and cell–cell interplay [40,41].Taken together, we provide evidence that supports
the effects of MUC4/Y in the malignant progression of
pancreatic cancer. These results on functional studies
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reported from experimental model of over-expression of
rat orthologue of MUC4 (rMuc4/SMC) [42,43] and mini-
MUC4[21], or silencing/knockdown of MUC4 (sh-MUC4)
[40,44,45]. Together with the positive correlation of
MUC4/Y with MUC4 expression in PDAC clinical sam-
ples, we have validated our reasoning that MUC4/Y is
involved in malignant progression similarly to FL-MUC4
and, consequently, MUC4/Y and its domain-lacking
models may be valuable tools for the further dissection
of MUC4-mediated functions and mechanisms.
Although we have pointed out the over-expression
and alternative splicing of MUC4 may create a favor-
able environment for tumor progression by triggering
malignancy-related positive feedback loops, it would
be more expected to further investigate the inter-
action and network between those key mediators and
their receptors, between involved signal pathways, as
well as between transcription factors in the formation
of circuit using new approaches like systems biology
and clinical bioinformatics.
Conclusions
The huge length of its gene fragment restricts the
functional and mechanism research of human MUC4.
As one of its splice variants, MUC4/Y with coding
sequence is mostly as similar as FL-MUC4. The level of
MUC4/Y mRNA expression in PDAC clinical samples in-
dicates that MUC4/Y is significantly positive-correlated
with tumor invasion and distant metastases. The positive
correlation between MUC4/Y and MUC4 expression levels
in PDAC clinical samples also suggests that MUC4/Y might
play similar roles as MUC4 in the malignant progression
of pancreatic cancer. Forced-expression MUC4/Y has
sub-cellular localization similar to that of wild-type MUC4,
suggesting similar protein processing in the transfection cell
model. Functional studies show that MUC4/Y enhances
cell model malignant activity in vitro and in vivo, including
proliferation under low-nutritional-pressure, resistance to
apoptosis, motility, invasiveness, angiogenesis, and distant
metastasis. Mechanism studies indicate the novel finding
that MUC4/Y triggers malignancy-related positive feed-
back loops for concomitantly up-regulating the expression
of survival factors to resist adverse microenvironment and
increasing the expression of an array of cytokines and
adhesion molecules to affect the tumor milieu. In light of the
enormity of the potential regulatory circuitry in cancer
afforded by MUC4 and/or MUC4/Y, repressing MUC4
transcription, inhibiting post-transcriptional regulation, in-
cluding alternative splicing, or blocking various pathways
simultaneously may be helpful for controlling malignant
progression. MUC4/Y- expression model is proven to
valuable tool for the further dissection of MUC4-mediated
functions and mechanisms.Additional file
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